Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 2/20 | 0.67 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL4614990 | 0.95 | CA5A (0.60) | CA5ACA5BCA2KDM4ECYP3A4 | |
| Sulfuric Acid SCHEMBL28003070 | 0.95 | CA5A (0.60) | CA5ACA5BCA2KDM4ECYP3A4 | |
| SCHEMBL128169 | 0.94 | — | — | |
| SCHEMBL8596055 | 0.94 | CA2 (0.58) | CA5ACA5BCA2KDM4ECYP3A4 | |
| SCHEMBL25599 | 0.94 | CA2 (0.58) | CA5ACA5BCA2KDM4ECYP3A4 | |
| SCHEMBL105 | 0.94 | — | — | |
| SCHEMBL246838 | 0.94 | CA2 (0.58) | CA5ACA5BCA2KDM4ECYP3A4 | |
| SCHEMBL15109974 | 0.94 | — | — | |
| Sulfuric Acid SCHEMBL27303947 | 0.91 | CA5A (0.55) | CA5ACA5BCA2KDM4ECYP3A4 | |
| SCHEMBL8729088 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114105822-B | Pseudo C 2 Symmetrical chiral diallyl substituted compound and preparation method and application thereof | 武汉大学 | 2023-12-01 | — | — | CN | claimed |
| CN-114105822-A | Pseudo C2Symmetrical chiral diallyl substituted compound and preparation method and application thereof | 武汉大学 | 2022-03-01 | — | — | CN | claimed |
| EP-2910545-B1 | METHOD FOR PRODUCING N,N-DIALKYLHOMOFARNESIC ACID AMIDE | KAO CORP (JP) | 2017-04-12 | — | — | EP | claimed |
| US-20110272273-A1 | LANTHANIDE-MEDIATED PHOTOCHEMICAL WATER SPLITTING PROCESS FOR HYDROGEN AND OXYGEN GENERATION | MOLYCORP MINERALS, LLC (US) | 2011-11-10 | — | — | US | claimed |
| WO-2011140561-A1 | LANTHANIDE-MEDIATED PHOTOCHEMICAL WATER SPLITTING PROCESS FOR HYDROGEN AND OXYGEN GENERATION | MOLYCORP MINERALS LLC (US) | 2011-11-10 | — | — | WO | claimed |
| CN-101928301-B | Method for synthesizing levofosfomycin dextrophenethylamine salt from dextrofosfomysin levophenethylamine salt | HUBEI XUNDA PHARMACEUTICAL CO LTD | 2011-08-31 | — | — | CN | claimed |
| US-20110045065-A1 | SUBSTANCE HAVING ANTIOXIDANT, GEROPROTECTIVE AND ANTI-ISCHEMIC ACTIVITY AND METHOD FOR THE PREPARATION THEREOF | MARVEL LIFE SCIENCES LTD. (GB) | 2011-02-24 | — | — | US | claimed |
| EP-2265253-A2 | ORAL DOSAGE FORM CONTAINING A PYRIDINOL DERIVATIVE | Marvel Lifesciences Limited (GB) | 2010-12-29 | — | — | EP | claimed |
| EP-2265252-A2 | OPHTHALMIC PREPARATION CONTAINING A PYRIDINOL DERIVATE | Marvel Lifesciences Limited (GB) | 2010-12-29 | — | — | EP | claimed |
| CN-101928301-A | Method for synthesizing levofosfomycin dextrophenethylamine salt from dextrofosfomysin levophenethylamine salt | HUBEI XUNDA PHARMACEUTICAL CO LTD | 2010-12-29 | — | — | CN | claimed |
| WO-2009116077-A2 | INJECTABLE PREPARATIONS AND A PROCESS OF PREPARATION THEREOF | M.J.BIOPHARM PVT. LTD. (IN) | 2009-09-24 | — | — | WO | claimed |
| WO-2009116076-A2 | STERILE OPTHALMIC PREPARATIONS AND A PROCESS FOR PREPARATION THEREOF | M. J. BIOPHARM PVT.LTD. (IN) | 2009-09-24 | — | — | WO | claimed |
| WO-2009116078-A2 | ORAL DOSAGE FORMULATIONS AND PROCESS OF PREPARATION THEREOF | M. J. BIOPHARM PVT. LTD. (IN) | 2009-09-24 | — | — | WO | claimed |
| US-20060040915-A1 | Process for the preparation of cefdinir | RANBAXY LABORATORIES LIMITED (IN) | 2006-02-23 | — | — | US | claimed |
| EP-0662475-B1 | Method for the preparation of 2-perfluoroalkyl-3-oxazolin-5-one | AMERICAN CYANAMID CO (US) | 1998-05-06 | — | — | EP | claimed |
| US-5659046-A | REACTING AN AMINONITRILE WITH A PERFLUOROACYLATING AGENT; CYCLIZATION | AMERICAN CYANAMID COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| EP-0662475-A2 | Method for the preparation of 2-perfluoroalkyl-3-oxazolin-5-one | AMERICAN CYANAMID COMPANY (US) | 1995-07-12 | — | — | EP | claimed |
| WO-1993010187-A1 | AGRICULTURAL BIODEGRADABLE PLASTICS | INTERNATIONAL OPTICAL TELECOMMUNICATIONS, INC. (US) | 1993-05-27 | — | — | WO | claimed |
| US-4323566-A | HISTAMINE H2 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1982-04-06 | — | — | US | claimed |
| EP-0016565-A1 | 1,2,4-Triazole derivatives, processes for their production and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1980-10-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045065-A1 | SUBSTANCE HAVING ANTIOXIDANT, GEROPROTECTIVE AND ANTI-ISCHEMIC ACTIVITY AND METHOD FOR THE PREPARATION THEREOF | GPX4, PGC, GSR | CA5A 1013/4885CA5B 762/4885CA2 3323/4885 |
| US-20060040915-A1 | Process for the preparation of cefdinir | DCXR, C1R, PEPD | CA5A 2630/4885CA5B 3019/4885CA2 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.